{"id":2290,"date":"2018-10-16T13:39:42","date_gmt":"2018-10-16T11:39:42","guid":{"rendered":"https:\/\/staging.blogs.yokogawa.de\/chemical-pharma\/uncategorized\/ci-what-is-it-actually-part-2\/"},"modified":"2022-06-17T09:28:27","modified_gmt":"2022-06-17T07:28:27","slug":"ci-what-is-it-actually-part-2","status":"publish","type":"post","link":"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/ci-what-is-it-actually-part-2\/","title":{"rendered":"CI &#8211; what is it actually? (Part 2)"},"content":{"rendered":"<h3><strong>CI as a target for cyber attacks (continued from the <\/strong><a href=\"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/de\/kritis-was-ist-das-eigentlich-teil-1\/\">blog post<\/a><strong> of October 8th, 2018)<\/strong><\/h3>\n<p>The German Federal Office for Information Security (BSI) issued a warning in mid-June that German utilities could be a target for large-scale cyber attack campaigns. Although no information is currently available on hackers having succeeded in gaining access, the BSI reports that it is nevertheless intensively investigating a number of suspicious cases and therefore advises taking suitable precautions (source: <a href=\"https:\/\/www.bsi.bund.de\/DE\/Presse\/Pressemitteilungen\/Presse2018\/Cyber_Angriffe_auf_deutsche_Energieversorger_13062018.html\">https:\/\/www.bsi.bund.de\/DE\/Presse\/Pressemitteilungen\/Presse2018\/Cyber_Angriffe_auf_deutsche_Energieversorger_13062018.html<\/a>). A successful cyber attack on systems that control physical and technical processes could well have a disruptive effect on the entire plant. The resulting downtime would have disastrous economic consequences. And cyber attacks which target safety facilities or procedures directly could potentially cause environmental damage or put human lives at risk. What particularly sticks in the mind are high-profile attacks like the ones on the Ukrainian power grid in 2015 and 2016 or malware infections like DragonFly and Stuxnet.<\/p>\n<h3>Unfortunately, these are real threats<\/h3>\n<p>This all goes to show that such threats are no longer just theoretically possible but unfortunately already a reality. Cybercriminals are actively attempting to get a foothold and \u201ccrack\u201d these sensitive networks. Black hat activists and state sponsored hackers use freely accessible data and information to form as precise a picture as possible about how the intended target works from a technical perspective. Using this information, they then initiate a tailored attack with the goal of manipulating or destroying physical systems. A Triconex Safety Instrumented System (SIS) was the target of one recent malware campaign. The aim of this attack was to cause disruption to the physical infrastructure by interacting with the SIS. (Link to blog post: <a href=\"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/?p=4384\">https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/cyber-attack-on-security-system-triton-malware\/<\/a>)<\/p>\n<h3><strong>Ingenious plant security solutions<\/strong><\/h3>\n<p>Many operators of critical infrastructures have already recognized that plant security measures are unable to keep pace with the rapid advance of digitalization and connectivity. Security is an ongoing challenge, and all-round protection to safeguard system stability and integrity calls for a holistic concept. Following a comprehensive analysis of the network architecture \u2013 ideally an assessment based on an asset inventory \u2013 customized solutions are developed to protect assets and their sensitive infrastructures throughout a (hopefully) long lifecycle.<\/p>\n<h3><strong>Lifecycle \u2013 plant availability<\/strong><\/h3>\n<p>There are various steps you can take to increase the chances of a long lifecycle: in the same way as you pay a visit to your doctor for a routine checkup, and if necessary take proactive or preventive measures to preserve or possibly restore your state of health, you should also keep a close watch on the \u201cstate of health\u201d of your assets. Yokogawa can help you identify your plant safety and security status, and take any action that is required to ensure permanent availability.<br \/>\nIn short, just like the human organism needs a healthy immune system, your plant needs a suitable safety and security concept.<\/p>\n<p>As operational technology (OT) specialists, we at Yokogawa pursue a defense-in-depth strategy. We not only comply with international industrial standards for OT (Functional Safety IEC 61511 plus Cyber Security ISA\/IEC 62443) and Information Technology (IT) ISO 27001 as well as with the relevant Namur &amp; BSI recommendations; we also meet your specific industry needs for an appropriate safety and security level. (<a href=\"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/de\/um-technische-synergien-effektiv-nutzen-zu-koennen-muessen-die-technologien-sicher-und-handhabbar-sein\/\">Click here to watch an interview on this subject with Chee Hoe Lee,\u00a0Yokogawa Electric Int. Global Cyber Security Evangelist, Security Consultant for Europe<\/a>)<\/p>\n<h3><strong>Where should I start?<\/strong><\/h3>\n<p>You\u2019re probably now asking where is the best place to start. Please don\u2019t hesitate to contact us: we\u2019d be delighted to develop a made-to-measure 360\u00b0 plant security concept for you featuring state-of-the-art technologies in line with international industrial standards. And help you profit from the wealth of opportunities arising from the digital transformation.<\/p>\n<p><a href=\"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/de\/kritis-was-ist-das-eigentlich-teil-1\/\"><em><strong>Click here to read Part 1 of this blog post!<\/strong><\/em><\/a><\/p>\n<p>&nbsp;<\/p>\n<blockquote class=\"wp-embedded-content\" data-secret=\"ZqGKX1xQ55\"><p><a href=\"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/safety-security-en\/are-my-house-or-plant-attractive-to-criminals-part-1\/\">Is my house or plant attractive to criminals? (Part 1)<\/a><\/p><\/blockquote>\n<p><iframe class=\"wp-embedded-content\" sandbox=\"allow-scripts\" security=\"restricted\" style=\"position: absolute; clip: rect(1px, 1px, 1px, 1px);\" title=\"&#8220;Is my house or plant attractive to criminals? (Part 1)&#8221; &#8212; Chemical Pharma Blog\" src=\"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/safety-security-en\/are-my-house-or-plant-attractive-to-criminals-part-1\/embed\/#?secret=sw3mPs8xld#?secret=ZqGKX1xQ55\" data-secret=\"ZqGKX1xQ55\" width=\"500\" height=\"282\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\"><\/iframe><\/p>\n<blockquote class=\"wp-embedded-content\" data-secret=\"0zmaJ0rF6v\"><p><a href=\"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/safety-security-en\/is-my-house-or-plant-attractive-to-criminals-part-2\/\">Is my house or plant attractive to criminals? (Part 2)<\/a><\/p><\/blockquote>\n<p><iframe class=\"wp-embedded-content\" sandbox=\"allow-scripts\" security=\"restricted\" style=\"position: absolute; clip: rect(1px, 1px, 1px, 1px);\" title=\"&#8220;Is my house or plant attractive to criminals? (Part 2)&#8221; &#8212; Chemical Pharma Blog\" src=\"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/safety-security-en\/is-my-house-or-plant-attractive-to-criminals-part-2\/embed\/#?secret=LOaQl3DxXU#?secret=0zmaJ0rF6v\" data-secret=\"0zmaJ0rF6v\" width=\"500\" height=\"282\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\"><\/iframe><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Critical infrastructures (CI) are organizations or institutions that are important to the state community and whose failure or disruption would result in supply bottlenecks with a lasting effect, major disruptions to public safety or other dramatic consequences: After all, we&hellip; <\/p>\n<p class=\"read-more\"> <a class=\"\" href=\"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/ci-what-is-it-actually-part-2\/\"> <span class=\"screen-reader-text\">CI &#8211; what is it actually? (Part 2)<\/span> Read More &raquo;<\/a><\/p>\n","protected":false},"author":117,"featured_media":2283,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"","footnotes":""},"categories":[59],"tags":[82,394,108,121,395,396,212,304,139,165,283,113,100,397,215,133],"coauthors":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.13 (Yoast SEO v20.13) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>CI - what is it actually? (Part 2) - Chemical Pharma Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/ci-what-is-it-actually-part-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CI - what is it actually? (Part 2)\" \/>\n<meta property=\"og:description\" content=\"Critical infrastructures (CI) are organizations or institutions that are important to the state community and whose failure or disruption would result in supply bottlenecks with a lasting effect, major disruptions to public safety or other dramatic consequences: After all, we&hellip;  CI &#8211; what is it actually? (Part 2) Read More &raquo;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/ci-what-is-it-actually-part-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Chemical Pharma Blog\" \/>\n<meta property=\"article:published_time\" content=\"2018-10-16T11:39:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-06-17T07:28:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.yokogawa.com\/eu\/blog\/app\/uploads\/sites\/8\/2022\/06\/Fotolia_188127382_S-768x417.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"768\" \/>\n\t<meta property=\"og:image:height\" content=\"417\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fatma Evren\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/ci-what-is-it-actually-part-2\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/ci-what-is-it-actually-part-2\/\"},\"author\":{\"name\":\"Fatma Evren\",\"@id\":\"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/#\/schema\/person\/bef25632a9874d43e7fe7dbe212050ad\"},\"headline\":\"CI &#8211; what is it actually? (Part 2)\",\"datePublished\":\"2018-10-16T11:39:42+00:00\",\"dateModified\":\"2022-06-17T07:28:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/ci-what-is-it-actually-part-2\/\"},\"wordCount\":663,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/#organization\"},\"keywords\":[\"Automation\",\"CI\",\"Communication\",\"Complexity\",\"Critical infrastructures\",\"Critical Systems\",\"Cyber Security\",\"Fatma Evren\",\"Industry 4.0\",\"IT security\",\"Plant Security\",\"plants\",\"process industry\",\"Safety and Scurity\",\"Safety system\",\"Test\"],\"articleSection\":[\"Safety &amp; Security\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/ci-what-is-it-actually-part-2\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/ci-what-is-it-actually-part-2\/\",\"url\":\"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/ci-what-is-it-actually-part-2\/\",\"name\":\"CI - what is it actually? (Part 2) - Chemical Pharma Blog\",\"isPartOf\":{\"@id\":\"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/#website\"},\"datePublished\":\"2018-10-16T11:39:42+00:00\",\"dateModified\":\"2022-06-17T07:28:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/ci-what-is-it-actually-part-2\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/ci-what-is-it-actually-part-2\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/ci-what-is-it-actually-part-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CI &#8211; what is it actually? (Part 2)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/#website\",\"url\":\"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/\",\"name\":\"Chemical Pharma Blog\",\"description\":\"Yokogawa&#039;s Chemical &amp; Pharma Blog\",\"publisher\":{\"@id\":\"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/#organization\",\"name\":\"Chemical Pharma Blog\",\"url\":\"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.yokogawa.com\/eu\/blog\/app\/uploads\/sites\/8\/2022\/05\/yokogawa-logo-e1651674418793.png\",\"contentUrl\":\"https:\/\/www.yokogawa.com\/eu\/blog\/app\/uploads\/sites\/8\/2022\/05\/yokogawa-logo-e1651674418793.png\",\"width\":302,\"height\":89,\"caption\":\"Chemical Pharma Blog\"},\"image\":{\"@id\":\"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/#\/schema\/person\/bef25632a9874d43e7fe7dbe212050ad\",\"name\":\"Fatma Evren\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/#\/schema\/person\/image\/705d9e7d4dc124ce066ce1502b785235\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9dfa0b587fc6749dc929dd6ff1c83bf0?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9dfa0b587fc6749dc929dd6ff1c83bf0?s=96&d=mm&r=g\",\"caption\":\"Fatma Evren\"},\"url\":\"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/author\/fatma-evren\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CI - what is it actually? (Part 2) - Chemical Pharma Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/ci-what-is-it-actually-part-2\/","og_locale":"en_US","og_type":"article","og_title":"CI - what is it actually? (Part 2)","og_description":"Critical infrastructures (CI) are organizations or institutions that are important to the state community and whose failure or disruption would result in supply bottlenecks with a lasting effect, major disruptions to public safety or other dramatic consequences: After all, we&hellip;  CI &#8211; what is it actually? (Part 2) Read More &raquo;","og_url":"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/ci-what-is-it-actually-part-2\/","og_site_name":"Chemical Pharma Blog","article_published_time":"2018-10-16T11:39:42+00:00","article_modified_time":"2022-06-17T07:28:27+00:00","og_image":[{"width":768,"height":417,"url":"https:\/\/www.yokogawa.com\/eu\/blog\/app\/uploads\/sites\/8\/2022\/06\/Fotolia_188127382_S-768x417.jpg","type":"image\/jpeg"}],"author":"Fatma Evren","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/ci-what-is-it-actually-part-2\/#article","isPartOf":{"@id":"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/ci-what-is-it-actually-part-2\/"},"author":{"name":"Fatma Evren","@id":"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/#\/schema\/person\/bef25632a9874d43e7fe7dbe212050ad"},"headline":"CI &#8211; what is it actually? (Part 2)","datePublished":"2018-10-16T11:39:42+00:00","dateModified":"2022-06-17T07:28:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/ci-what-is-it-actually-part-2\/"},"wordCount":663,"commentCount":0,"publisher":{"@id":"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/#organization"},"keywords":["Automation","CI","Communication","Complexity","Critical infrastructures","Critical Systems","Cyber Security","Fatma Evren","Industry 4.0","IT security","Plant Security","plants","process industry","Safety and Scurity","Safety system","Test"],"articleSection":["Safety &amp; Security"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/ci-what-is-it-actually-part-2\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/ci-what-is-it-actually-part-2\/","url":"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/ci-what-is-it-actually-part-2\/","name":"CI - what is it actually? (Part 2) - Chemical Pharma Blog","isPartOf":{"@id":"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/#website"},"datePublished":"2018-10-16T11:39:42+00:00","dateModified":"2022-06-17T07:28:27+00:00","breadcrumb":{"@id":"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/ci-what-is-it-actually-part-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/ci-what-is-it-actually-part-2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/ci-what-is-it-actually-part-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/"},{"@type":"ListItem","position":2,"name":"CI &#8211; what is it actually? (Part 2)"}]},{"@type":"WebSite","@id":"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/#website","url":"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/","name":"Chemical Pharma Blog","description":"Yokogawa&#039;s Chemical &amp; Pharma Blog","publisher":{"@id":"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/#organization","name":"Chemical Pharma Blog","url":"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.yokogawa.com\/eu\/blog\/app\/uploads\/sites\/8\/2022\/05\/yokogawa-logo-e1651674418793.png","contentUrl":"https:\/\/www.yokogawa.com\/eu\/blog\/app\/uploads\/sites\/8\/2022\/05\/yokogawa-logo-e1651674418793.png","width":302,"height":89,"caption":"Chemical Pharma Blog"},"image":{"@id":"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/#\/schema\/person\/bef25632a9874d43e7fe7dbe212050ad","name":"Fatma Evren","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/#\/schema\/person\/image\/705d9e7d4dc124ce066ce1502b785235","url":"https:\/\/secure.gravatar.com\/avatar\/9dfa0b587fc6749dc929dd6ff1c83bf0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9dfa0b587fc6749dc929dd6ff1c83bf0?s=96&d=mm&r=g","caption":"Fatma Evren"},"url":"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/author\/fatma-evren\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/www.yokogawa.com\/eu\/blog\/app\/uploads\/sites\/8\/2022\/06\/Fotolia_188127382_S.jpg",940,511,false],"thumbnail":["https:\/\/www.yokogawa.com\/eu\/blog\/app\/uploads\/sites\/8\/2022\/06\/Fotolia_188127382_S-150x150.jpg",150,150,true],"medium":["https:\/\/www.yokogawa.com\/eu\/blog\/app\/uploads\/sites\/8\/2022\/06\/Fotolia_188127382_S-300x163.jpg",300,163,true],"medium_large":["https:\/\/www.yokogawa.com\/eu\/blog\/app\/uploads\/sites\/8\/2022\/06\/Fotolia_188127382_S-768x417.jpg",768,417,true],"large":["https:\/\/www.yokogawa.com\/eu\/blog\/app\/uploads\/sites\/8\/2022\/06\/Fotolia_188127382_S.jpg",940,511,false],"1536x1536":["https:\/\/www.yokogawa.com\/eu\/blog\/app\/uploads\/sites\/8\/2022\/06\/Fotolia_188127382_S.jpg",940,511,false],"2048x2048":["https:\/\/www.yokogawa.com\/eu\/blog\/app\/uploads\/sites\/8\/2022\/06\/Fotolia_188127382_S.jpg",940,511,false],"post-thumbnail":["https:\/\/www.yokogawa.com\/eu\/blog\/app\/uploads\/sites\/8\/2022\/06\/Fotolia_188127382_S-356x200.jpg",356,200,true]},"uagb_author_info":{"display_name":"Fatma Evren","author_link":"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/author\/fatma-evren\/"},"uagb_comment_info":0,"uagb_excerpt":"Critical infrastructures (CI) are organizations or institutions that are important to the state community and whose failure or disruption would result in supply bottlenecks with a lasting effect, major disruptions to public safety or other dramatic consequences: After all, we&hellip; CI &#8211; what is it actually? (Part 2) Read More &raquo;","_links":{"self":[{"href":"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/wp-json\/wp\/v2\/posts\/2290"}],"collection":[{"href":"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/wp-json\/wp\/v2\/users\/117"}],"replies":[{"embeddable":true,"href":"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/wp-json\/wp\/v2\/comments?post=2290"}],"version-history":[{"count":1,"href":"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/wp-json\/wp\/v2\/posts\/2290\/revisions"}],"predecessor-version":[{"id":11110,"href":"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/wp-json\/wp\/v2\/posts\/2290\/revisions\/11110"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/wp-json\/wp\/v2\/media\/2283"}],"wp:attachment":[{"href":"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/wp-json\/wp\/v2\/media?parent=2290"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/wp-json\/wp\/v2\/categories?post=2290"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/wp-json\/wp\/v2\/tags?post=2290"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.yokogawa.com\/eu\/blog\/chemical-pharma\/en\/wp-json\/wp\/v2\/coauthors?post=2290"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}